Dexcom: Stelo Rollout and Record Margins Ignite Price Momentum
Reading Time: 2 minutes
The successful introduction of the over-the-counter Stelo system opens up massive new patient groups for Dexcom beyond insulin dependency. A significant trading volume above the 100-day average confirms institutional investors' confidence in the new growth phase. Aspiring mid-term targets and a share buyback program underpin the growth story! DexCom is considered a global pioneer in continuous glucose monitoring (CGM). Dexcom develops highly precise sensors that measure blood sugar levels in real time and transmit the data directly...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
